TABLE 4.
Genotype | Pegasys dose weekly | Ribavirin dose daily | ||
---|---|---|---|---|
1 or 4 | 180 μg | Weight <75 kg = 1000 mg/day | ||
Weight ≥75 kg = 1200 mg/day | ||||
2 or 3
|
180 μg
|
800 mg (regardless of weight)
|
||
Pegetron* (pegylated interferon-alpha-2b) and ribavirin doses | ||||
Weight (kg) |
Pegetron RediPen* or vial strength to use |
Amount of Pegetron to administer weekly (μg) |
Volume of Pegetron to administer weekly (mL) |
Ribavirin dose to administer daily (mg) |
<40 | 50 μg/0.5 mL | 50 | 0.5 | 800 |
40–<50 | 80 μg/0.5 mL | 64 | 0.4 | 800 |
50–<64 | 80 μg/0.5 mL | 80 | 0.5 | 800 |
64–<75 | 120 μg/0.5 mL | 96 | 0.4 | 1000 |
75–<85 | 120 μg/0.5 mL | 120 | 0.5 | 1000 |
≥85 | 150 μg/0.5 mL | 150 | 0.5 | 1200 |
Hoffmann-La Roche Ltd, Canada;
Hoffmann-La Roche Inc, USA
Schering-Plough Canada Inc